This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Pharmacy benefit managers’ incentives to self-preference, engage in exclusionary rebates warrant more scrutiny, US FTC says

By Khushita Vasant ( July 9, 2024, 12:45 GMT | Insight) -- Concentration among pharmacy benefit managers is increasing, with vertical integration having raised various competitive concerns in the drug supply chain in the US as well as financial conflicts of interest which should be investigated further, the Federal Trade Commission said today. The FTC published a 73-page interim staff report on the prescription drug middleman industry.Concentration among pharmacy benefit managers is increasing, with vertical integration having raised various competitive concerns in the drug supply chain in the US as well as financial conflicts of interest which should be investigated further, the Federal Trade Commission said today....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login